$1.50
-0.06 (-3.85%)
Open$1.53
Previous Close$1.56
Day High$1.55
Day Low$1.46
52W High$2.60
52W Low$1.14
Volume—
Avg Volume162.5K
Market Cap172.34M
P/E Ratio—
EPS$-0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,429.3% upside
Current
$1.50
$1.50
Target
$37.94
$37.94
$25.58
$37.94 avg
$45.71
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 60.16M | 53.18M | 50.95M |
| Net Income | -7,561,680 | -6,775,030 | -7,233,045 |
| Profit Margin | -12.6% | -12.7% | -14.2% |
| EBITDA | -8,587,792 | -7,436,735 | -8,070,839 |
| Free Cash Flow | -10,429,515 | -10,842,286 | -7,296,543 |
| Rev Growth | -4.1% | +12.5% | -5.7% |
| Debt/Equity | 1.23 | 1.43 | 1.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |